Figure 1From: A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumorsPatient flowchart. DLT, dose-limiting toxicity; QOD, every other day; QW, every week.Back to article page